<DOC>
	<DOCNO>NCT02580474</DOCNO>
	<brief_summary>Safety Efficacy DAAs ( Daclatasvir+Asunaprevir ) patient chronic hepatitis C chronic renal failure assess .</brief_summary>
	<brief_title>The Safety Efficacy Daclatasvir Asunaprevir With Chronic HCV Genotype 1b Infection Chronic Renal Failure</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>HCV RNA Positive Genotype 1b No history sign symptom decompensated liver disease hepatocellular carcinoma within 6 month A patient dialysis , MDRD eGFR &lt; 30ml/min HCV treatment history : HCV treatmentnaive participant , define never receive HCV treatment approve investigational drug ( include vaccine ) ; OR HCV treatmentexperienced , define receive previous HCV treatment ( pegylated ) interferon ( [ Peg ] IFN ) base drug regimen ( without ribavirin [ RBV ] include directacting antiviral agent [ DAA ] ) . Last dose previous HCV treatment course occur least 2 month prior screen No baseline mutation NS5A polymorphism include L31F/I/M/V Y93H A patient receive Daclatasvir Asunaprevir Pregnant woman , woman breastfeed believe may wish become pregnant course study Evidence medical condition contribute chronic liver disease HCV seropositive HIV Diagnosed suspect hepatocellular carcinoma malignancy Any history , current evidence , clinical hepatic decompensation ( e.g. , ascites , encephalopathy variceal hemorrhage ) Received solid organ bone marrow transplant Current alcohol substance abuse judge investigator potentially interfere subject compliance Significant renal , cardiovascular , pulmonary , neurological disease uncontrolled diabetes hypertension opinion investigator Known hypersensitivity study drug , metabolite , formulation excipients Who take investigational drug within 2 month .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>